Vaccine, Antibody Race On As Omicron Spreads In China
Outbreaks Complicate 'Zero COVID' Policy Ahead Of Winter Olympics
An oral vaccine candidate from Hong Kong and domestically-developed antivirals and antibodies join the ongoing development fight as Tianjin city reports new Omicron outbreak.
You may also be interested in...
China's main pharma hub of Shanghai reported sector output has plunged by more than half due in large part to the prolonged lockdown, while 58% of surveyed foreign companies in China across all industries project declining revenue.
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.